ImageneBio is a clinical-stage biopharmaceutical company developing therapeutics for immunological, autoimmune and inflammatory diseases, with its lead asset IMG-007 being a non-depleting anti-OX40 monoclonal antibody designed to treat conditions such as atopic dermatitis, alopecia areata, asthma, rheumatoid arthritis, and hidradenitis suppurativa. The company licenses the underlying technology from Hutchmed and outsources manufacturing, with its revenue model based on achieving development and regulatory milestones, sales-based milestones, and tiered royalties on global net sales. ImageneBio intends to commercialize IMG-007 either through partnerships with established pharmaceutical companies or by building an in-house commercialization capability, targeting large markets with significant unmet medical needs where existing approved therapies face efficacy limitations and safety concerns.